Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
Support Care Cancer. 2022 Sep;30(9):7431-7438.
DOI: 10.1007/s00520-022-07143-x
A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
Clin Cancer Res. 2022 Jul 12 (Online ahead of print)
DOI: 10.1158/1078-0432.CCR-22-1238
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Cancer Res Treat. 2022 Mar 24. (Online ahead of print)
DOI: 10.4143/crt.2021.1561.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Cancer. 2022 Feb 15;128(4):778-787.
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
Korean J Intern Med. 2022 Jan;37(1):190-200.
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Gastric Cancer. 2022 May;25(3):609-618.
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Cancer Res Treat. 2022 Jan;54(1):1-9.